| Literature DB >> 26273574 |
Abstract
All vaccines are developed to elicit an effective immune response in vaccinated animals such as innate, humoral and cell mediated response to protect animal health. Quality and intensity of the immune responses are differing by characteristics of the vaccine formulation and nature of the infectious agent. Modified live virus vaccines showed advantages over killed vaccines in terms of rapid immune response, duration of the immunity and better cell mediated protection mechanism. The porcine reproductive and respiratory syndrome virus (PRRSV) is relatively newly emerging (1986 in United States, 1990 in Europe) viral pathogen in pigs and tremendous effort has been made to protect pigs from this economically devastating disease such as developing killed, modified live, recombinant protein based and DNA vaccines. However, only cell culture attenuated virus vaccine is practiced with arguably limited efficacy. The PRRSV vaccine did not clear virus from infected pigs nor prevent re-infection of the virus. The vaccine showed very limited innate immune response, low anamnestic immune response and negligible cell mediated immune response. Despite of the current developed scientific technology, there still remain many questions to solve a most important pig disease worldwide.Entities:
Keywords: Immunity; Porcine respiratory and reproductive syndrome virus; Vaccines
Year: 2015 PMID: 26273574 PMCID: PMC4524900 DOI: 10.7774/cevr.2015.4.2.159
Source DB: PubMed Journal: Clin Exp Vaccine Res ISSN: 2287-3651
Fig. 1Relationship between pig mortality and antibody avidity to porcine reproductive and respiratory syndrome virus (PRRSV) was investigated in pig farms. Mortality of over 15%, 10%-15%, 5%-10%, and less than 5% were grouped and avidity of the antibody to PRRSV was determined. Reproduced from Seo and Sunwoo (2012), Proceeding of the 22nd International Pig Veterinary Society Congress [7].
Arterivirus proteins modulating innate immune signaling
| Virus | Protein | Modulatory function for innate immunity |
|---|---|---|
| PRRSV | nsp1 | Inhibits production of type I IFNs and impairs IFN promoter activity |
| Suppresses NF-κB activation | ||
| Induces CBP degradation | ||
| Suppresses TNF-α promoter activity | ||
| nsp1 | Inhibits production of type I IFNs and impairs IFN promoter activity | |
| Impairs IRF3 phosphorylation and IRF3 nuclear localization | ||
| Interferes with IFN-α induction and ISG expression | ||
| nsp2 (PLP2) | Blocks nuclear translocation of ISGF3 by inducing KPNA1 degradation | |
| Suppresses TNF-α promoter activity | ||
| Antagonizes type I interferon induction | ||
| Interferes with NF-κB signaling pathway | ||
| Prevents IκBα degradation by OTU domain | ||
| Inhibits ISG15 production and ISGylation | ||
| Activates NF-κB | ||
| nsp4 | Inhibits IFN-13 promoter activity | |
| Suppresses NF-κB mediated signaling pathway in the nucleus | ||
| nsp11 | Impair IFN promoter activity | |
| Participates in suppression of RIG-I signaling | ||
| Degrades mRNA of IPS-1 | ||
| Inhibits production of type I IFNs and impairs IFN promoter activity | ||
| N | Impairs IRF3 phosphorylation and IRF3 nuclear localization | |
| Upregulates IL-10 gene expression | ||
| Activates NF-κB | ||
| EAV | nsp1 | Inhibits production of type I IFNs and impairs IFN promoter activity |
| nsp2 (PLP2) | Inhibits RIG-I-mediated innate immune signaling | |
| Inhibits RIG-I ubiquitination by its DUB activity | ||
| LDV | nsp1 | Inhibits production of type I IFNs and impairs IFN promoter activity |
| Induces CBP degradation | ||
| nsp1 | Inhibits production of type I IFNs and impairs IFN promoter activity | |
| SHFV | nsp1 | Inhibits production of type I IFNs and impairs IFN promoter activity |
Han and Yoo. Virus Res 2014;194:100-9 [1].
PRRSV, porcine reproductive and respiratory syndrome virus; nsp, nonstructural protein; IFN, interferon; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; CBP, CREB-binding protein; TNF, tumor necrosis factor; IRF, interferon regulatory transcription factor; ISG, interferon-stimulated gene; PLP, papain-like cysteine protease; ISGF, interferon-stimulated gene factor; KPNA, karyopherin alpha 1; IκBα, NF-κB1; OTU, ovarian tumor; IL, interleukin.
Fig. 2The porcine reproductive and respiratory syndrome virus (PRRSV) infection and repertoire of the immune response in the virus infected pigs. Reproduced from Lopez and Osorio (2004), Elsevier, Veterinary Immunology and Immunopathology [11]. ELISA, enzyme-linked immunosorbent assay; IFN-γ, interferon γ.
Fig. 3Antibody maturation leads virus clearance in the vaccinated pigs after challenge. Pigs were vaccinated and virus in the blood and avidity of the antibody specific to porcine reproductive and respiratory syndrome virus (PRRSV) was monitored. Reproduced from Seo and Sunwoo (2012), Proceeding of the 22nd International Pig Veterinary Society Congress [7].